BIOLICAN- INSERM- AAP Research Company(s) 2019 (Q3683260)

From EU Knowledge Graph
Revision as of 16:17, 24 November 2021 by DG Regio (talk | contribs) (‎Changed an Item: Edited by the beneficiary bot - attach the beneficiary based on the string)
Jump to navigation Jump to search
Project Q3683260 in France
Language Label Description Also known as
English
BIOLICAN- INSERM- AAP Research Company(s) 2019
Project Q3683260 in France

    Statements

    0 references
    295,632.0 Euro
    0 references
    397,402.0 Euro
    0 references
    74.39 percent
    0 references
    1 January 2020
    0 references
    31 December 2022
    0 references
    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    0 references
    0 references
    BIOLICAN vise à développer un dispositif technologique innovant non invasif capable de détecter des signatures moléculaires spécifiques dans le sang des patients atteints de cancer du poumon afin d’améliorer le diagnostic précoce et la prise en charge de la maladie. (French)
    0 references
    BIOLICAN aims to develop an innovative non-invasive technological device capable of detecting specific molecular signatures in the blood of lung cancer patients in order to improve early diagnosis and management of the disease. (English)
    18 November 2021
    0 references

    Identifiers

    MP0021775
    0 references